Although President Obama has favored funding for embryonic stem cell research, the moral debate continues. But that discussion may overshadow the fact that biotech companies have actually made the most early progress, not in embryonic stem cells, but in adult stem cells. Dr. Robert Harman, chief executive officer and founder of Vet-Stem, joins the Chicago Tribune's Bruce Japsen. Vet-Stem is using stem-cell therapy in veterinary regenerative medicine that may one day benefit humans. In this interview, they discuss adult stem cells, and the major momentum in research and commercialized treatments.
Beyond the Embryonic Stem Cell Debate
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Although President Obama has favored funding for embryonic stem cell research, the moral debate continues. But that discussion may overshadow the fact that biotech companies have actually made the most early progress, not in embryonic stem cells, but in adult stem cells. Dr. Robert Harman, chief executive officer and founder of Vet-Stem, joins the Chicago Tribune's Bruce Japsen. Vet-Stem is using stem-cell therapy in veterinary regenerative medicine that may one day benefit humans. In this interview, they discuss adult stem cells, and the major momentum in research and commercialized treatments.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?